Efficacy of Thumb-tack Needle Treatment for Diminished Ovarian Reserve

Launched by XIAOMEI SHAO · Jan 16, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment for women dealing with Diminished Ovarian Reserve (DOR), which is a condition that can lead to difficulties in becoming pregnant. The researchers are looking at a special type of acupuncture called thumb-tack needle treatment to see if it can help improve ovarian function. Women between the ages of 18 and 40 who have been diagnosed with DOR may be eligible to participate in this study. To qualify, they need to have specific hormone levels and should not be receiving other treatments for their condition.

Participants in this trial can expect to receive the thumb-tack needle treatment during the study period. It’s important to note that women who are currently pregnant, breastfeeding, or have certain medical conditions will not be able to join. This study is currently recruiting participants, and those who volunteer will be helping to determine if this new acupuncture method can be an effective way to support fertility in women with DOR.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 18 years old ≤ age \< 40 years old, female;
• * Clinical diagnosis of Diminished Ovarian Reserve: meet both items in twice tests with an interval of at least 4 weeks(tested between 2rd to 4th day of menstrual cycle):
• • 1. 10 IU/L \< FSH \< 20 IU/L,
• • 2. Anti-Müllerian hormone(AMH) \< 1.1ng/mL.
• • without any mind disease, willing to participate in the study and sign the informed consent.
• • without any other treatment.
• Exclusion Criteria:
• • Low or no response to exogenous gonadotropins, or with congenital anomalies in the development of the reproductive tract；
• • Pregnant or breastfeeding;
• • Abnormal body temperatures at the moment;
• • Psychopath, alcoholic, Patient with severe depression, history of substance abuse and severe primary diseases of cardiovascular, liver, kidney and hematopoietic system;
• • Currently enrolled in other clinical trials or refuse to cooperate with the study protocol.